Welcome to the LTC Pharmacy Podcast.  Our goal is to pass on the passion for long term care pharmacy.  We hope this is both entertaining and educational.  And Tamara will do her best to keep Scott in line!

Are you looking to offer compliance packaging in your community but don’t know where to start?  Or do you already have a solution, but are struggling to scale it? 

Evaluating literature around microdosing, drug interactions, recent clinical research, and more!

***Disclaimer: this podcast is intended for informational purposes only on the safety and efficacy data of the substances discussed. As healthcare professionals, we do not advocate for or against the use of substances which are considered illicit by the United States Drug Enforcement Administration***

References:

Bonson KR, et al. Chronic administration of serotonergic anti-depressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology. 1996; 14(6)

Gasser P, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of Nervous and Mental Disease. 2014; 202(7): 513-520

Lopez-Gimenez JF, Gonzalez-Maeso J. Hallucinogens and Serotonin 5HT2A Receptor Mediated Signaling Pathways. Current Topics in Behavioral Neuroscience. 2018; 36: 45-73

Liechti ME. Modern Clinical Research on LSD. Neuropsychopharmacology. 2017; 42: 2114-2127.

Murphy RJ, et al. MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers. Trials. 2021; 22. https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05243-3

Murphy RJ, et al. Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial. Biological Psychiatry. 28 March 2023. https://www.biologicalpsychiatryjournal.com/article/S0006-3223(23)01164-2/fulltext#gr2

Passie T, et al. The pharmacology of lysergic acid diethylamide: a review. CNS Neuroscience and Therapeutics. 11 Nov 2018. https://onlinelibrary.wiley.com/doi/10.1111/j.1755-5949.2008.00059.x

Ashton Maaraba has spent 20 years bring exciting new products and services to independent pharmacy. Most of them deploying major new technological capabilities. Now he has taken the helm of IPC Digital Health. In this episode he outlines the 5 Pillars that form the foundation for IPC's continuing efforts to future proof pharmacy. Maaraba indicates that telehealth, remote patient monitoring, adherence programs, operational efficiency and new patient care services such lab testing will provide pharmacies with the ability to generate much needed non-dispensing or PBM dependent revenue.

Guys how rare is it that we get TWO members of the Pharmacy Podcast Network combining our efforts to give YOU the best episode we can! We talk all pharmacy things! How business owners can improve their profit line NOW and even what the future outlook of pharmacy looks like. Dr. Lisa Faast is what she has deemed a "Pharmacy Badass"! I have to agree with her because she is pretty intuitive when it comes to independent pharmacy. She's out here trying to save our profession, y'all! Get tickets to their next event here: https://2023.pharmacyprofitsummit.com/2023-summit#open-popup I have been to a few of the "Pharmacy Profit Summits" and it will NOT disappoint! 

Dr. Dave Kisor, a professor and director of pharmacogenomics at Manchester University. He graduated from The Ohio State University College of Pharmacy in 1986 and completed a two-year fellowship in therapeutic drug monitoring/pharmacokinetics at OSU. Before he joined Manchester, Dave was professor of pharmaceutical sciences at Ohio Northern University after being a research scientist at Burroughs Wellcome Co/GlaxoWellcome. Dave has over 80 peer-reviewed publications including being the lead author on two pharmacogenomics textbooks. He is a past chair of the American Association of Colleges of Pharmacy (AACP) Pharmacogenomics Special Interest Group. Dave was named a Fellow of the American College of Clinical Pharmacology in 2017, and in 2021, along with Dr. Tom Smith, he received an AACP Innovations in PGx Teaching Award. His current research is related to PGx and opioid use disorder. Dave currently serves as co-chair of the Pharmacogenomics Global Research Network (PGRN) Education Committee and is Editor-In-Chief of Pharmacogenomics: Foundations, Competencies, and the Pharmacists’ Patient Care Process.

House Energy and Commerce Committee cleared a PBM bill that seems to contain more transparency loopholes and makes more limited policy tweaks to the drug supply chain middleman than the Senate HELP Committee’s bill, but the House-side legislation would pull back the curtain on specialty-drug reimbursement in a way the Senate version does not. 

On this episode, we introduce Framework Focus, a brand-new podcast that connects the Long-Term Pharmacy ecosystem, hosted by FrameworkLTC's very own Dr. Mark Fulton. In this conversation, Mark shares with Todd a little bit about the podcast and what to expect in the months to come. He also previews the FrameworkLTC User Conference happening this Fall in Boston.

Integra X Files blog contributor Paul Baldwin joins us for a two-part conversation on how pharmacists can expand their practice. In Part 1, he discusses the history and potential of the pharmacy industry, the benefits of caregiving, and the role of pharmacists in healthcare innovation and progress.